EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CMG Pharmaceutical Co. Ltd (058820) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of CMG Pharmaceutical Co. Ltd KRW 828, price KRW 562, upside +47.4%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7058820002

CP Thin data Oct 2, 2026

CMG Pharmaceutical Co. Ltd

058820 · KQ

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value 828.13 KRW · Undervalued (+47.4%)
Low debt
Expensive Growth (revenue 5y +10.3 %/yr in KRW)
Thin margins · 4.0% net margin (TTM)
Quality 30/100
Negative free cash flow
Trails peers (2/8)
Narrow moat 21/100
Thin data
Watch CMG Pharmaceutical Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

5,510 KRW 536.00 KRW Fair Value 828.13 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 536.00 KRW – 5,510 KRW · fair‑value band 618.01 KRW – 1,236 KRW · the 562.00 KRW price screens below the 828.13 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 2, 2026.

Follow CMG Pharmaceutical Co. in your weekly email

Every Wednesday you see whether CMG Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis.

Show more

CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.

Stock analysis

CMG Pharmaceutical Co. Ltd (058820) currently trades at 562.00 KRW, while our model-based Fair Value estimate is 828.13 KRW, implying the stock looks roughly 32.1% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 618.01 KRW (bear) to 1,236 KRW (bull), the price of 562.00 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CMG Pharmaceutical Co. Ltd reported revenue of 105B KRW in FY2025 versus 69.5B KRW in FY2021, a compound +10.9%/yr. Reported net income was −10.1B KRW in FY2025.

Key figures

Market cap 83.1B KRW (≈ $61.9M) · P/S ratio 0.72 · Net margin −9.6% · Return on equity 2.3% · Return on assets (EBIT) 1.1% · Operating margin −10.4% · Revenue (TTM) 116B KRW · Revenue growth (YoY) +24.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 74% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 47%, 058820 screens cheaper than that median.

Fair Value models

Bear 618.01 KRW Fair Value 828.13 KRW Bull 1,236 KRW
Price 562.00 KRW · Upside +47.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 680.36 KRW 911.68 KRW 1,361 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 680.36 KRW 911.68 KRW 1,361 KRW 54

Open the full fair value analysis →

Notify me when 058820 reaches fair value

Put 058820 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 30/100

Of which business quality 30 · Market factors (momentum, volatility) 18

Profitability 12
Margins and returns on capital today
Quality Growth 41
Are margins and returns improving?
Cashflow 13
Earnings quality: real cash, not paper profit
Fin. Strength 45
Balance sheet, leverage, solvency risk
Investment 41
Disciplined investing over empire-building
Low Volatility 58
Calm price path (market factor)
Momentum 2
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 39
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +14.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.9% (2020) → −3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 058820, get fair value alerts →

Compare CMG Pharmaceutical Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside +47.4% · Top 25%
Profitability
Return on equity (TTM) 2.3% · Below median
Return on assets −0.7% · Bottom 25%
Net margin (TTM) 4.0% · Below median
Operating margin (TTM) −10.4% · Bottom 25%
Growth and dividend
Revenue growth 24.7% · Top 25%
Balance sheet
Debt / equity 0.18× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)97 · sector 17
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)9 · sector 27
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CMG Pharmaceutical Co. Ltd · Fair Value
828.13 KRW +32%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CMG Pharmaceutical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/058820

Frequently asked questions

Is CMG Pharmaceutical Co. Ltd (058820) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 828.13 KRW versus a price of 562.00 KRW, about +47% upside (undervalued).
What is the fair value of 058820?
Our model-based fair value for CMG Pharmaceutical Co. Ltd is 828.13 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 562.00 KRW.
What is the quality score of 058820?
CMG Pharmaceutical Co. Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CMG Pharmaceutical Co. Ltd (058820)?
Our model-based price target is the fair value of 828.13 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 618.01 KRW, optimistic scenario 1,236 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CMG Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at 828.13 KRW, about +47% upside versus a price of 562.00 KRW (undervalued). Cautious scenario 618.01 KRW, optimistic scenario 1,236 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CMG Pharmaceutical Co. Ltd (058820)?
CMG Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about 116B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of CMG Pharmaceutical Co. Ltd (058820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CMG Pharmaceutical Co. Ltd it is 828.13 KRW per share (as of Oct 2, 2026), against a price of 562.00 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CMG Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 058820 trades below its calculated fair value: price 562.00 KRW, fair value 828.13 KRW, a gap of about +47% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 058820?
No. The price is what the market pays today (562.00 KRW); the fair value is what the company's own numbers justify (828.13 KRW). For CMG Pharmaceutical Co. Ltd the two are 266.13 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CMG Pharmaceutical Co. Ltd worth?
The market values CMG Pharmaceutical Co. Ltd at about 83.1B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 562.00 KRW; our models calculate a fair value of 828.13 KRW per share.
What do the bullish and bearish scenarios say about 058820?
Our models span a range for CMG Pharmaceutical Co. Ltd: cautious scenario 618.01 KRW, base 828.13 KRW, optimistic 1,236 KRW per share (as of Oct 2, 2026, price 562.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CMG Pharmaceutical Co. Ltd (058820)?
Balance-sheet figures for CMG Pharmaceutical Co. Ltd (as of Oct 2, 2026): return on equity 2.3%, debt of 0.18 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 058820 from its 52-week high?
CMG Pharmaceutical Co. Ltd trades at 562.00 KRW, about 74% below its 52-week high of 2,140 KRW and 5% above the low of 536.00 KRW (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of 828.13 KRW is for.
Which stocks are comparable to CMG Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CMG Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price 562.00 KRW, calculated fair value 828.13 KRW (+47%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 058820 calculated?
We run CMG Pharmaceutical Co. Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 828.13 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CMG Pharmaceutical Co. Ltd currently trades 32 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CMG Pharmaceutical Co. Ltd (058820)?
The closing price on Sep 30, 2026 was 562.00 KRW. Our model-based fair value is 828.13 KRW, about +47% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CMG Pharmaceutical Co. Ltd right now?
The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (618.01 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (618.01 KRW to 1,236 KRW) leaves room in how you read the outcome.

Key figures of CMG Pharmaceutical Co. Ltd

How large is the market capitalisation of CMG Pharmaceutical Co. Ltd (058820)?
The market capitalisation of CMG Pharmaceutical Co. Ltd is 83.1B KRW (≈ $61.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CMG Pharmaceutical Co. Ltd (058820)?
The price-to-sales ratio of CMG Pharmaceutical Co. Ltd is 0.72 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CMG Pharmaceutical Co. Ltd (058820)?
The net margin of CMG Pharmaceutical Co. Ltd is −9.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CMG Pharmaceutical Co. Ltd (058820)?
The return on equity (ROE) of CMG Pharmaceutical Co. Ltd is 2.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CMG Pharmaceutical Co. Ltd (058820)?
On an EBIT basis the return on assets of CMG Pharmaceutical Co. Ltd is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CMG Pharmaceutical Co. Ltd (058820)?
The operating margin of CMG Pharmaceutical Co. Ltd is −10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CMG Pharmaceutical Co. Ltd (058820)?
Revenue at CMG Pharmaceutical Co. Ltd is growing +24.7% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CMG Pharmaceutical Co. Ltd (058820)?
Earnings per share at CMG Pharmaceutical Co. Ltd are growing +6.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CMG Pharmaceutical Co. Ltd (058820) generate?
The free cash flow of CMG Pharmaceutical Co. Ltd is −44.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CMG Pharmaceutical Co. Ltd (058820) carry?
The net debt of CMG Pharmaceutical Co. Ltd is 65.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CMG Pharmaceutical Co. Ltd in the live analysis

One click puts CMG Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.